Xipiro developed a molecule, pNaKtide, that acts on a Master Control Switch to halt the generation of ROS. pNaKtide can be capitalized across a series of indications. With initial focus on ROP, Xipiro is raising to fully fund IND-enabling studies.
Science Background: https://www.dropbox.com/s/twteo0v4sp83j6h/Xipiro%20Science%20Foundation.pdf?dl=0 Background Articles: https://www.dropbox.com/s/8kabigze9cph630/Articles.zip?dl=0 IOVS Article: https://iovs.arvojournals.org/article.aspx?articleid=2772032
Pitch Deck: https://www.dropbox.com/s/jfzk5ew85zhloa4/XIPIRO%20Intro.pdf?dl=0
Orphan Indication Status + Priority Review Voucher Applications: $100k MILESTONE (+6 months): Orphan Indication Status granted and acceptance into the PRV program ---- Manufactured GMP-Batch of XIP-100: $300k MILESTONE (+3 months): Completed GMP batch of XIP-100 ---- IND-Enabling Studies: $2.5 million MILESTONE (+18 months): Completed toxicology, bioanalysis methods and pharmacology studies and ability to submit to FDA for Phase I Clinical Trial clearance